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Abstract 
Background: Recent evidence suggests that glucosidase beta acid (GBA) mutations 
predispose Parkinson’s disease (PD) patients to a greater burden of cognitive impairment 
and non-motor symptoms. This emerging knowledge has not yet been considered in 
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patients who have undergone deep brain stimulation (DBS); a surgery that is generally 
contraindicated in those with cognitive deficits. 
Objective: To explore the long-term phenotypic progression of GBA-associated PD, in a DBS 
cohort. 
Methods: Thirty-four PD patients who had undergone DBS surgery between 2002 and 2011 
were included in this study; 17 patients with GBA mutations were matched to 17 non-
carriers. Clinical evaluation involved the administration of four assessments: The Mattis 
Dementia Rating Scale was used to assess cognitive function; non-motor symptoms were 
assessed using the Non-Motor Symptom Assessment Scale for PD; quality of life was 
measured using the Parkinson’s Disease Questionnaire; and motor symptoms were 
evaluated using part III of the Movement Disorders Society Unified Parkinson’s Disease 
Rating Scale, in on-medication/on-stimulation conditions. Levodopa equivalent doses (LED) 
and DBS settings were compared with clinical outcomes. 
Results: At a mean follow-up of 7.5 years after DBS, cognitive impairment was more 
prevalent (70% vs 19%) and more severe in GBA mutation carriers compared to non-carriers 
(60% vs 6% were severely impaired). Non-motor symptoms were also more severe and 
quality of life more impaired in GBA-associated PD. Motor symptoms, LED, and stimulation 
settings were not significantly different between groups at follow-up. 
Conclusions: GBA status appears to be an important predictor for non-motor symptom 
disease progression, after deep brain stimulation surgery. 
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1. Introduction 
Parkinson’s disease (PD) is characterised clinically by motor symptoms [1], however, a host 
of non-motor symptoms also commonly occur. These include olfactory dysfunction, 
cognitive impairment, autonomic dysfunction, psychiatric symptoms, sleep disturbance, 
pain, and fatigue [2]. These symptoms can be very disabling and are associated with 
reduced health-related quality of life [3, 4]. 
While Levodopa is the most effective treatment for PD, it has significant limitations [5] 
including motor and non-motor fluctuations, dyskinesia, and psychosis [6]. Deep brain 
stimulation (DBS) surgery is a well-established treatment for the motor symptoms of PD, 
which involves the implantation of electrodes into the bilateral subthalamic nuclei (STN) or 
the globi pallidii interni (GPi) [7]. How DBS exerts its action is still not clear [8], however, in 
cases of DBS in the STN, its effectiveness allows for dopaminergic medication to be reduced 
post-operatively, which most certainly contributes to the reduction in drug-induced 
dyskinesias reported after surgery. DBS has been reported to significantly improve quality of 
life but is not a suitable option for everyone with PD. The contraindications to its usage 
include the presence of clinically relevant speech difficulties and cognitive impairment. 
These features may be exacerbated after DBS [9]. 
The clinical presentation of patients with PD is highly variable, which likely reflects a 
complicated interplay of environmental and genetic factors. Mutations in the glucosidase 
beta acid (GBA) gene are the most common genetic risk factor for developing PD [10] and 
have been associated with a more aggressive disease course. Evidence emerging over the 
preceding decade suggests GBA mutations predispose carriers to an earlier age of onset [10-
13], accelerated progression of motor impairment [14-17], a greater burden of non-motor 
 4 
symptoms [18], and reduced quality of life [19]. Reports suggest that GBA associated PD 
carries a greater risk of cognitive impairment compared to idiopathic PD [10, 13, 18-24]. 
However, the evidence reporting the clinical correlates of GBA-associated PD are based on a 
small number of patients and there are some uncorroborated and conflicting findings [25-
27]. Further evidence is therefore required to elucidate the clinical features associated with 
GBA-associated PD.  
The aim of this study was to investigate the clinical features of PD patients, with and 
without GBA mutations, after deep brain stimulation surgery, exploiting the regular and 
detailed assessments that take place in this cohort of patients both before and after 
surgery, to explore whether outcomes differ according to GBA mutation status. 
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2. Materials and Methods 
Study design 
This is a case-control study following 34 PD patients, with and without GBA mutations, after 
DBS surgery. Preoperative data were collected for each patient without knowledge of GBA 
status. Postoperative clinical assessments were completed in a non-blinded fashion.  
Participants 
All patients underwent DBS surgery between 2001 and 2011 at the National Hospital for 
Neurology and Neurosurgery (NHNN), London. Patients had been diagnosed according to 
the UK Parkinson’s Disease Brain Bank criteria and selected for surgery by a movement 
disorder multi-disciplinary team, following a battery of clinical assessments [15, 28]. DBS 
surgery was performed using an MRI-guided and MRI-verified technique described by 
Foltynie et al. [29]. All patients provided consent to genetic testing and were screened for 
mutations in SNCA, PARKIN, PINK1, DJ-1, LRRK2 and GBA. Genetic testing was performed by 
the Neurogenetics Unit at the NHNN, between 2008 and 2011, as previously described [15]. 
From this cohort, 17 patients with GBA mutations were identified (GBA+) in addition to a 
further 17 patients (GBA-) who were selected according to matched sex and disease 
duration to the GBA+ group, by an individual (VL) who had no previous contact with them, 
or knowledge of any of their clinical details.  
The GBA+ group included 15 heterozygous mutation carriers, 1 homozygous carrier, and 1 
compound heterozygote. Two patients also carried a mutation in another PD-associated 
gene; PARKIN or LRRK2. The 17 patients who did not carry a GBA mutation (GBA-) were also 
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negative for mutations in the other genes tested. All patients had previously consented to 
genotyping for PD genetic risks (REC number 08/H0715/121). 
Clinical assessment 
Postoperative clinical evaluation involved the administration of four validated assessments: 
The Mattis Dementia Rating Scale (DRS-2) was used to assess cognitive function; the 
assessment consists of 36 tasks comprising five subscales that provide information on 
specific abilities: attention, initiation/perseveration, constructional ability, conceptualisation 
and memory. A total raw score ranging from 0 to 144 is based on performance in all five 
subscales, with higher scores conferring better cognitive function. Age-corrected scores (the 
Age-Corrected Mayo’s Older Americans Normative Studies (MOANS) Scaled Score; AMSS) 
were obtained from the raw total score and each subscale score [30]. 
The severity of non-motor symptoms was assessed using the Non-Motor Symptom 
Assessment Scale for PD (NMSS); the scale comprises 30 items, each relating to a specific 
non-motor symptom. The items are classified in nine domains: cardiovascular, sleep/fatigue, 
mood/cognition, perceptual problems/hallucinations, attention/memory, gastrointestinal 
tract, urinary, sexual function and miscellaneous [31]. Domain scores are computed by the 
summation of the corresponding item scores, and for the total NMSS score by the sum of 
the domains [32]. 
Motor symptoms were evaluated using part III of the Movement Disorder Society (MDS)-
sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS-III). 
Subscores for cardinal motor symptoms were derived by summation of the relevant items 
from the MDS-UPDRS as follows: axial symptoms (for example, speech and postural 
instability) (items 3.1, 3.2, 3.9-3.14), rigidity (item 3.3), bradykinesia (items 3.4-3.8) and 
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tremor (items 3.15-3.18). Quality of life was measured using the Parkinson’s Disease 
Questionnaire (PDQ-39). 
Participants were administered all assessments on a single day, which were completed in 
the same order. Each patient’s medication was recorded and their levodopa equivalent dose 
(LED) was calculated using a standard formula [33]. Stimulation settings were also 
documented during this time. All clinical assessments were performed with patients on-
medication and on-stimulation. 
Preoperative data, collected during the screening process for DBS surgery, were retrieved.  
 
Statistical analysis 
Mean scores and standard deviations were calculated for all continuous data and 
percentages were calculated for categorical values. Continuous data were checked for 
normality using the Shapiro-Wilk test (p = 0.05). If normally distributed, the unpaired 
Student’s t-test was used to compare GBA+ patients and GBA- patients. Alternatively, the 
Mann-Whitney U test was performed for non-parametric data. Categorical data was 
compared between groups using the Pearson’s chi-squared test, if the sample size was 
sufficient, or the Fisher’s exact test. All reported p values are two-sided at a significance 
level of 0.05. Statistical tests were performed using the Stata 12.1 statistical software 
package (StataCorp LC, College Station, TX). 
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3. Results 
Demographics 
Demographic characteristics of the 34 participants followed in this study are presented in 
Table 1. 
Despite being matched by disease duration, the mean age at surgery was 4 years younger in 
GBA+ patients, compared to non-carriers (t=-2.7, p = 0.015). Two GBA+ patients were 
selected for GPi DBS (based on the severity of dyskinesias) and all others underwent STN 
DBS. The mean time since DBS surgery was 7.5 ± 2.0 years (range, 3.4 to 11.8 years) across 
all participants. At follow-up, 3 GBA+ patients (18%) and 1 GBA- patient (6%) were 
deceased. Furthermore, 2 GBA+ patients (12%) were unable to complete follow-up 
assessment due to severe PD-related disability and 2 could not be contacted (see Figure 1). 
The remaining 26 patients completed follow-up clinical assessment (10 GBA+; 16 GBA-).
There were no significant differences in the stimulation settings between GBA+ patients and 
GBA- patients at follow-up. However, the mean stimulation amplitude was higher in GBA+ 
patients (3.8±0.8 V) compared to GBA- patients (3.1±0.8 V). Pulse width was also slightly 
higher in the GBA+ group (66.0±10.5 μs vs 63.8±8.7 μs). Conversely, stimulation frequency 
was higher in GBA- patients (114.7±31.3 Hz vs 102.5±37.1 Hz).  
Cognitive scores 
At follow-up, the cognitive performance of GBA+ patients was significantly worse than GBA- 
patients (t=-3.1, p = 0.006; Table 2). The mean AMSS scores of GBA mutation carriers were 
consistently lower across all five cognitive domains. Seven of 10 (70%) GBA+ patients were 
cognitively impaired compared to 3 of 16 (19%) GBA- patients (χ2 = 6.8, p = 0.009). 
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Moreover, cognitive impairment was more severe in GBA+ associated PD. Six (60%) 
cognitively impaired GBA+ patients were considered severely impaired. Among GBA- 
patients with cognitive impairment, only 1 (6%) demonstrated severe cognitive impairment. 
According to clinical guidelines used to select candidates for DBS, all patients were 
cognitively intact preoperatively; although 2 patients performed below average (1 GBA+; 1 
GBA-). There was no significant difference in pre-operative cognitive performance, however, 
due to the variability in the neuropsychological tools used preoperatively, DRS-2 scores 
were available for only 16 patients.  
Non-motor scores 
The mean total NMSS score was significantly higher for GBA+ compared to GBA- (t = 3.2, p = 
0.004; Table 3) indicating a greater burden of non-motor symptoms in this group. The mean 
scores of the GBA+ group were higher across all domains, except cardiovascular symptoms, 
which is marginally lower. Notably, the mean score for attention/memory in GBA+ patients 
was more than double that of GBA- patients. Preoperative NMSS scores were not available 
for the study cohort, as it was not routinely administered prior to DBS at the time of their 
surgery. 
Quality of life scores 
Compared to GBA- patients at follow-up, GBA+ patients reported significantly worse quality 
of life (t= 2.2, p = 0.040). The GBA+ group demonstrated greatest deterioration in mobility, 
activities of daily living, cognition, and communication (Table 4). The quality of life of 
patients, with and without GBA mutations, did not differ preoperatively. 
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Motor scores 
Preoperative, on-medication motor scores did not differ significantly between patients with 
GBA mutations and those without mutations (Table 5). However, off-medication, 
preoperative total UPDRS-III scores were significantly higher in the GBA+ group (t=2.7, p = 
0.009)), indicating greater motor impairment in this group. Analysis of UPDRS-III scores 
show that rigidity and axial symptoms were significantly worse in the GBA+ group (t= 2.6, p 
= 0.015 and t =2.3, p = 0.026, respectively). Tremor and bradykinesia were not significantly 
different between GBA+ and GBA- groups. 
At follow-up, the on-medication MDS-UPDRS-III scores were higher among GBA+ patients 
with accompanying higher motor scores in all domains except tremor, however, none of 
these motor comparisons achieved conventional thresholds for statistical significance. 
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4. Discussion 
Clinical features of GBA-associated PD after deep brain stimulation (DBS) 
The results of this study are consistent with previous reports, that GBA status influences the 
natural progression of disease, in a DBS cohort. Although age at onset, preoperative 
cognition, and quality of life were similar between PD patients with and without GBA 
mutations, GBA+ patients required DBS earlier in their disease course, suggesting a faster 
rate of progression. This is also reflected in their preoperative, off-medication motor 
performance. The observation that 5 GBA+ patients could not participate in follow-up 
assessment, due to severe disability or death, supports this suggestion. An increased rate of 
mortality has been demonstrated in GBA mutation carriers [17]. Importantly, the loss of 
these 5 patients from follow-up represents a bias, as those who had/have the greatest 
disease severity could not be included in follow-up analysis. As a consequence, the 
differences found between GBA+ and GBA- patients at follow-up are likely to be 
underestimates. 
Follow-up data revealed cognitive impairment to be more prevalent (70% vs 19%) and more 
severe (60% vs 6% were severely impaired) in GBA mutation carriers, corroborating a 
growing body of evidence that find GBA mutations increase the risk and rate of cognitive 
decline. These findings correlate with pathological reports of a higher density of Lewy 
pathology in the neocortex of these patients [13, 34, 35]. The DRS-2 performance of those 
with GBA-associated PD conformed to the expected pattern of PD, and mimicked the 
pattern of non-carriers, with lowest scores in the construction and initiation/perseveration 
domains [36]. This indicates that GBA status does not alter the form of cognitive impairment 
but influences the rate of cognitive decline. This contrasts with the findings of a large, 
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multicentre study that found GBA mutations to be associated with a distinct cognitive 
profile characterised by greater impairment in working memory, executive function and 
visuospatial abilities in PD patients [37]. 
GBA mutation carriers exhibited a greater burden of non-motor symptoms at follow-up. The 
prevalence and spectrum of non-motor symptoms appeared indistinguishable between 
groups, but the severity of symptoms was much worse in GBA-associated PD; particularly 
sleep/fatigue, attention/memory, gastrointestinal, and urinary symptoms.  
At a mean follow-up of 7.5 years, the quality of life of GBA- patients had almost returned to 
the preoperative status, after a period of effective DBS therapy [15]. Although there are 
very few reports of long-term outcomes after DBS, this finding is consistent with a review, 
which found quality of life in PD patients significantly improved 1 year post-DBS and back to 
baseline by 5 years follow-up [38]. For GBA+ patients, the mean quality of life score was, 
however, significantly worse at follow-up. This finding corroborates the results of a previous 
study which investigated the impact of GBA status on quality of life, irrespective of DBS [19]. 
According to previous reports, it can be inferred that the reduced quality of life observed in 
GBA mutation carriers is directly related to their increased burden of non-motor symptoms 
[3, 4]. It must be noted that the mean ‘emotional’ score of GBA+ patients was slightly higher 
than GBA- patients, denoting lower mood. Depression has been reported one of the main 
determinants of quality of life in PD and it is plausible that a low mood would impact on an 
individual’s self-assessment of most domains of quality of life [39]. 
Given the accumulating evidence implicating GBA mutations with a greater severity of non-
motor symptoms, it has been suggested that GBA mutations predispose carriers to a more 
aggressive disease. The mean total MDS-UPDRS-III score was 11 points higher in GBA 
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mutation carriers, accompanied by higher stimulation settings and higher LED requirements. 
There are a number of small studies that have suggested GBA mutations increase the 
severity of motor symptoms. While this may be evident when assessed off-medication or in 
the later aspects of disease, it appears likely that patients are responsive to dopamine 
replacement based on our pre-operative comparisons which are consistent with those of a 
recent meta-analysis which found no statistical difference between the UPDRS-III scores of 
646 GBA+ patients and 10,344 GBA- in the on-medication state [27].  
Clinical relevance 
Determining the effects of genetic mutations on PD phenotype is important to improve our 
ability to counsel PD patients as to their likely disease course. In GBA-associated PD, the 
reported incidence of increased burden of non-motor symptoms, particularly the increased 
likelihood and accelerated cognitive decline, can be a great source of concern for patients 
and their families. A personalised medicine approach involves providing patients with 
greater certainty about their individual prognosis and enhancing their ability to make 
informed decisions about therapeutic choices. 
Notably, not all GBA mutation carriers demonstrate the clinical features associated with 
more aggressive disease. In this report, 30% of GBA mutation carriers who completed the 
DRS-2 at follow-up were cognitively intact. Similarly, some individuals with GBA-associated 
PD reported less severe non-motor symptoms and better quality of life than some non-
carriers. Although these individuals are exceptions to the emerging trend observed in GBA-
associated PD, it is clear that there are other factors determining the clinical outcomes of PD 
patients and further research is required to understand what these additional modifiers are.  
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As the ultimate aim of DBS for PD is to improve the quality of life of patients, results 
presented here suggest that GBA status may be an important consideration when weighing 
the benefits and major risks associated with the surgery. According to their PDQ-39 follow-
up assessment, by a mean time of 8.6 years post-operatively, GBA mutation carriers’ quality 
of life becomes worse compared to their preoperative scores. One could speculate that 
these patients are less responsive to the effects of DBS or perhaps only benefit for a short 
time period, presumably due to more rapid progression of PD. Whether the decline 
observed is the result of GBA mutations alone or because of an interaction between GBA 
status and DBS is not known. These results might, however, suggest the use of bilateral GPi-
DBS, rather than bilateral STN-DBS, may be favourable because additional negative 
cognitive consequences, such as diminished verbal fluency, have been reported in STN-DBS 
[40-42]. 
There are several limitations that should be taken into consideration when reviewing the 
findings of this study. GBA mutation carriers were matched for sex and disease duration, as 
both motor and non-motor symptoms are primarily influenced by the duration of 
symptoms. Nevertheless, other variables may have influenced the outcome measures. This 
study explores phenotypic differences in a DBS cohort who were selected as appropriate 
candidates during pre-operative screening. Accordingly, the results presented here should 
be considered in this context, as data may not be representative of the wider PD population. 
Individuals who undergo DBS tend to have a young age at onset, which holds true in the 
study cohort who had a mean age at onset of 42 years. Additionally, to be eligible for 
surgery, patients must not have exhibited clinically relevant cognitive impairment or 
neuropsychiatric disturbance. 
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The greatest limitation of the study is sample size. The relatively small number of patients in 
each group limits the power of the study to reach definite conclusions. Furthermore, 
despite our best efforts at matching the 2 groups, there are small but non-significant 
differences between the groups in terms of age and disease duration that may partly 
contribute to the different rates of progression that we have observed. Nevertheless, the 
magnitude of the differences that emerge despite the small sample size are consistent with 
the emerging view that GBA+ patients have a more aggressive form of PD. 
The findings presented here require validation in larger patient cohorts to explore the 
relevance of different GBA mutations on phenotype and investigate whether zygosity 
influences the clinical presentation of carriers. Furthermore, it would be of interest to 
investigate the clinical outcomes of GBA mutation carriers, according to DBS target. In 
conclusion, GBA status appears to be an important predictor for non-motor symptom 
disease progression in PD. These results associate GBA mutations with more prevalent and 
more severe cognitive impairment and a greater burden of non-motor symptoms. Together, 
these findings suggest that GBA mutations predispose carriers to a more aggressive form of 
PD.  
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Table 1 Demographic characteristics of GBA+ and GBA- patients 
 
  
 GBA+ patients 
(n=17) 
GBA- patients 
(n=17) 
P value 
Gender distribution 10 male, 7 female 10 male, 7 female  
Ethnicity 16 white British, 1 Cambodian 17 white British  
Time since onset b (years) 21.0±7.8 21.7±6.0 0.782 
Time since surgeryb (years) 7.9±1.6 7.3±2.3 0.426 
Age at onset (years) 41.4±5.8 43.0±5.3 0.395 
Age at surgery (years) 53.5±4.5 57.7±4.4 0.015 
DBS target 15 STN, 2 GPi 17 STN 0.485 
Alive/deceased 14 alive, 3 deceased 16 alive, 1 deceased 0.301 
Preoperative LED (mg) 1296.9±665.2 1392.6±808.0 0.986 
Follow-up LEDb (mg) 1024.8±755.3 790.4±345.7 0.290 
a Continuous values are mean ± standard deviation unless otherwise stated. 
b Data available for 10 GBA+ patients and 16 GBA- patients. 
Abbreviations: n = number of patients; DBS = deep brain stimulation; STN = subthalamic nucleus;  
GPi = globus pallidus internus; LED = levodopa equivalent dose. 
 22 
Table 2 Cognitive performance of GBA+ patients and GBA- patients 
 
 
 
 
 
 
 
 
 
  
  GBA+ patients 
(n=10) 
GBA- patients       
(n=16) 
P value 
Preoperative Total DRS-2 AMSS c 12.5±2.3 13.2±2.6 0.506 
Follow-up Total DRS-2 AMSS 5.8±4.6 11.0±3.8 0.006 
 Attention AMSS 9.2±2.7 11.5±1.9  
 Initiation/perseveration AMSS 5.5±3.6 8.4±3.0  
 Construction AMSS 6.3±3.7 9.4±1.9  
 Conceptualisation AMSS 8.1±3.1 11.3±1.6  
 Memory AMSS 7.8±4.6 10.3±2.5  
a Values are mean ± standard deviation unless otherwise stated. 
b All scores are on a scale of 2 to 18. Higher scores denote better cognitive performance. 
c Data available for 10 GBA+ patients and 6 GBA- patients. 
Abbreviations: n = number of patients; DRS-2 = Mattis Dementia Rating Scale; AMSS = Age-corrected Mayo’s 
Older Americans Normative Studies (MOANS) Scaled Score. 
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Table 3 Non-motor performance of GBA+ patients and GBA- patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 GBA+ patients     
(n=10) 
GBA- patients       
(n=16) 
P value 
Total NMSS score 90.6±21.5 57.7±27.5 0.004 
 Cardiovascular 2.0±4.3 2.4±3.7  
 Sleep/fatigue 19.4±8.4 12.8±8.3  
 Mood/cognition 10.5±10.0 9.9±9.6  
 Perceptual problems 2.8±4.2 1.4±2.8  
 Attention/memory 10.3±10.8 4.1±6.8  
 Gastrointestinal 11.5±9.1 6.8±5.0  
 Urinary 19.1±9.8 10.8±10.4  
 Sexual function 9.2±7.3 4.0±4.1  
 Miscellaneous 5.8±4.0 5.5±5.8  
a Values are mean ± standard deviation unless otherwise stated. 
b Higher scores denote greater non-motor symptom burden. 
Abbreviations: n = number of patients; NMSS, Non-motor symptom assessment scale for 
Parkinson’s disease. 
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Table 4 Quality of life scores of GBA+ patients and GBA- patients 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  GBA+ patients   
(n=10) 
GBA- patients       
(n=16) 
P value 
Preoperative PDQ-39 SI  31.7±10.0 31.6±12.6 0.711 
Follow-up PDQ-39 SI 42.8±10.0 30.8±15.6 0.040 
 Mobility 75.5±12.8 52.7±32.0  
 ADL 58.3±27.1 40.9±29.9  
 Emotional 27.9±18.7 24.7±19.4  
 Stigma 21.9±20.0 16.0±21.5  
 Support 10.8±11.8 9.9±14.3  
 Cognition 46.9±18.9 30.9±21.8  
 Communication 64.2±27.2 39.6±26.3  
 Bodily discomfort 35.0±27.2 31.3±23.7  
a Values are mean ± standard deviation unless otherwise stated. 
b All scores are on a scale of 0 to 100. Higher scores denote reduced quality of life. 
Abbreviations: n = number of patients; PDQ-39 = Parkinson’s Disease Questionnaire; SI 
= summary index; ADL = activities of daily living. 
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Table 5 Motor performance of GBA+ patients and GBA- patients 
   GBA+ patients     
(n=17) 
GBA- patients       
(n=17) 
P value 
Preoperative scores 
 Total UPDRS-III 18.4±14.9 12.6±7.4 0.196 
 Axial symptoms 4.6±4.4 2.7±1.7 0.243 
 Tremor 1.0±1.5 1.4±2.7 0.925 
 Rigidity 5.4±4.3 2.9±2.1 0.092 
 Bradykinesia 7.4±6.9 5.6±4.3 0.387 
 Total UPDRS-III 52.4±13.0 40.5±12.0 0.009 
 Axial symptoms 13.3±5.4 9.4±4.1 0.026 
 Tremor 6.4±4.9 5.6±4.7 0.640 
 Rigidity 11.5±4.0 8.2±3.4 0.015 
 Bradykinesia 21.2±6.5 17.3±7.0 0.105 
Follow-up scoresc 
 
Total MDS-UPDRS-III 50.0±17.1 38.9±14.0 0.093 
 Axial symptoms 15.8±4.6 11.6±7.1 0.128 
 Tremor 3.1±4.3 3.3±3.7 0.678 
 Rigidity 9.1±5.1 6.3±3.5 0.111 
 Bradykinesia 22.0±9.8 17.8±7.3 0.230 
a Values are mean ± standard deviation unless otherwise stated. 
b Higher scores denote greater disability. 
c Data available for 9 GBA+ patients and 16 GBA- patients; 1 GBA+ patient did not complete motor 
assessment due to having his DBS hardware removed in May 2016, following erosion of the hardware. 
Abbreviations: n = number of patients; UPDRS-III =  Part III of the Unified Parkinson’s Disease Rating Scale;  
MDS-UPDRS-III = Part III of the Movement Disorder Society-sponsored Unified Parkinson’s Disease Rating 
Scale. 
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Figure 1. Flowchart of patients. GBA + and GBA – patients were matched at baseline for sex 
and disease duration, by an individual blind to subsequent outcome.  
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